BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This advanced composite formulation features poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) hydrogel-encapsulated doxorubicin liposomes (DOX-Lip-Gel) designed with a matrix-reinforced architecture. The structural framework consists of high-purity phospholipid vesicles encapsulating hydrophilic doxorubicin hydrochloride (DOX), which are thoroughly embedded within a thermosensitive biodegradable poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) (PLGA-PEG-PLGA) copolymer hydrogel network. This multi-layered composite matrix restricts the passive diffusion of the anthracycline drug and enhances mechanical resistance against osmotic stress, providing a sustained dual-barrier release profile.
Source
Custom synthesis
Functional Group
PLGA-PEG-PLGA; Doxorubicin
Form
Solid or powder
Purity
≥95%
Impurities
No visible impurities to the naked eye.
Identity
HPLC/MS/NMR
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.